We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Pioneering Collaboration to Transform Pediatric Cancer Diagnostics and Research

By LabMedica International staff writers
Posted on 11 Aug 2025

Cancer remains the leading cause of disease-related death after infancy in the U. More...

S., despite being rare in children and adolescents. In 2024, nearly 15,000 children and teens were expected to be diagnosed with cancer, with around 1,500 deaths projected. Diagnosing these cancers can be complex due to their rarity and molecular diversity. Now, a new collaborative clinical research and testing initiative aims to address these challenges by creating a suite of clinical assays tailored to rare pediatric cancers.

The new initiative, named BrightSeq (Boston Research in Innovative Genomics for Hematologic and Tumor Sequencing), is the result of pioneering collaboration between Dana-Farber Cancer Institute (Boston, MA, USA), Boston Children’s Hospital (Boston, MA, USA), and Broad Clinical Labs (Boston, MA, USA). Each partner leads a specific part of the process: Dana-Farber oversees patient engagement and translational assay innovation, Boston Children’s Hospital handles clinical variant interpretation, and Broad Clinical Labs manages sequencing and bioinformatics in a CLIA/CAP-certified facility.

BrightSeq’s product suite focuses on somatic molecular testing for suspected pediatric solid tumors and sarcomas. It includes CLIA-validated assays for whole exome sequencing (WES) of tumor samples, ultra-low pass whole genome sequencing (ULPWGS), and custom hybrid capture sequencing of liquid biopsies. These tools enable tumor fraction estimation and profiling of somatic alterations relevant to pediatric cancers. The suite is designed to support both clinical decision-making and genomic discovery.

The foundation for BrightSeq was built on earlier research from Dana-Farber’s pediatric oncology group and Broad scientists, which showed circulating tumor DNA (ctDNA) is a meaningful biomarker in pediatric solid tumors. This finding supported integrating liquid biopsy into routine pediatric cancer care. Philanthropic support helped translate this foundational science into the operational BrightSeq platform, now being implemented.

By returning actionable genomic insights to care teams, BrightSeq enhances patient management while advancing research through expanded sample collection and molecular analysis. The initiative’s goal is twofold: improve diagnostics and outcomes for young cancer patients, and fuel discovery across pediatric oncology through innovative genomics.

“This collaborative model will empower us to address urgent needs in pediatric cancer research while also returning critical results to patients and families,” noted Dr. Kimberly Stegmaier, Chair of the Department of Pediatric Oncology at Dana-Farber Cancer Institute.

"BrightSeq exemplifies our commitment to precision diagnostics for children with cancer. The clinical and research benefits of this platform will be significant and immediate," said Dr. Mark D. Fleming, Pathologist-in-Chief, Boston Children’s Hospital.

“BrightSeq blends genomics innovation with scalable clinical operations. We’re proud to help create a framework that supports both care delivery and discovery,” added Dr. Niall Lennon, Chair and Chief Scientific Officer at Broad Clinical Labs.

Related Links:
Dana-Farber Cancer Institute 
Boston Children's Hospital
Broad Clinical Labs 


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
New
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A simple blood sample that allows DNA methylation could identify epigenetic biomarkers (Photo courtesy of 123RF)

Simple Blood Sample Could Identify Epigenetic Biomarkers to Predict CVD Risk in Type 2 Diabetes

People with type 2 diabetes face up to four times higher risk of cardiovascular events such as heart attacks, strokes, and angina compared to individuals without the condition. Yet, current tools used... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The new technology could predict who will benefit from immunotherapy (Photo courtesy of Max Delbrück Center)

New Technology Deciphers Immune Cell Communication to Predict Immunotherapy Response

A healthy immune system depends on complex communication between specialized cell types that detect, alert, and eliminate harmful threats. When these immune signaling pathways break down, the result can... Read more

Microbiology

view channel
Image: MycoMEIA Aspergillus Assay is the first FDA-cleared urine-based test for invasive aspergillosis (Photo courtesy of Pearl Diagnostics)

Urine-Based Assay Diagnoses Common Lung Infection in Immunocompromised People

Invasive Aspergillosis (IA), a life-threatening fungal infection, poses a serious threat to immunocompromised individuals, especially those with hematologic malignancies, transplants, or severe lung diseases.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.